|
[1]
|
FITZER-ATTAS CJ,SCHINDLER DG,WAKS T,et al.Direct T cell activation by chimeric single chain Fv-Syk promotes Syk-Cbl association and Cbl phosphorylation[J].J Biol Chem,1997,272(13):8551. |
|
[2]
|
SONG DG,YE Q,POUSSIN M,et al.CD27 costimulation augmengts the surval and antitumoe activity of redirected human T cells in vivo[J].Blood,2002,119(3):696. |
|
[3]
|
PEGRAM HJ,LEE JC,HAYMAN EG,et al.Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning[J].Blood,2012,119(18):4133. |
|
[4]
|
KOCHENDERFER JN,ROSENBERG SA.Treating B-cell cancer with T-cells expressing anti-CD19 chimeric antigen receptors[J].Nat Rev Clin Oncol,2013,10(5):267. |
|
[5]
|
JUNE CH,BlAZAR BR,RILEY JL.Engineering lymphocyte subsets:tools,trials and tribulations[J].Nat Rev Immunol,2009,9(10):704. |
|
[6]
|
PORTER DL,LEVINE BL,KALOS M,et al.Chimeric antigen receptormodified T cells in chronic lymphoid leukemia[J].N Ensl J Med,2011,365(8):725. |
|
[7]
|
KALOS M,LEVINE BL,PORTTER DL,et al.T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia[J].Sci Transl Mad,2011,3(95):95ra73. |
|
[8]
|
PORTER DL,FREY NV,MELENHORST JJ,et al.Randomized,Phase Ⅱ Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19(CTL019) in Patients with Relapsed,Refractory CLL[J].Blood,2014,124(21):1982. |
|
[9]
|
PORTER DL,HWANG WT,FREY NV,et al.Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chroniclymphocytic leukemia[J].Sci Transl Med,2015,7(303):303ra139. |
|
[10]
|
KOCHENDERFER JN,DUDLEY ME,CARPENTER RO,et al.Donorderived anti-CD19 chimeric antigen receptor expressing T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation[J].Blood,2013,122(25):4129. |
|
[11]
|
DAVILA ML,KLOSS CC,GUNSET G,et al.CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia[J].PLoS One,2013,8(4):e61338. |
|
[12]
|
MAUS MV,GRUPP SA,PORTER D,et al.Antibody-modified T cells:CARs take the front seat for hematologic malignancies[J].Blood,2014,123(17):2625. |
|
[13]
|
DAVILA ML,RIVIERE I,WANG X,et al.Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia[J].Sci Transl Med,2014,6(224):224ra25. |
|
[14]
|
MAUDE SL,FREY N,SHAW PA,et al.Chimeric antigen receptor T cells for sustained remissions in leukemia[J].N Engl J Med,2014,371(16):1507. |
|
[15]
|
LEE DW,KOCHENDERFER JN,STETLER-STEVENSON M,et al.T cell sexpressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults:a phase 1 dose-escalation trial[J].Lancet,2015,385(9967):517. |
|
[16]
|
KRANICK S,PHAN G,KOCHENDERFER J,et al.Aphasia as a complication of CD19-targeted chimeric antigen receptor immunotherapy[J].Neurology,2014,82(10 Suppl):S52. |
|
[17]
|
GMPPSA,KALOS M,BARRETT D,et al.Chimeric antigen receptor-modified T cells for acute lymphoid leukemia[J].N Engl J Med,2013,368(16):1509. |
|
[18]
|
JONSE SA,SCHELLER J,ROSE-JOHN S.Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling[J].Clin Invest,2011,121(9):3375. |
点击查看大图
下载:
